deltatrials
Completed PHASE2/PHASE3 NCT00425373

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients

Sponsor: Novartis Pharmaceuticals

Conditions Essential Hypertension
Interventions Amlodipine 2.5 mg Amlodipine 5 mg Placebo Valsartan + amlodipine 40/2.5 mg Valsartan + amlodipine 40/5 mg Valsartan + amlodipine 80/2.5 mg Valsartan + amlodipine 80/5 mg Valsartan 40 mg Valsartan 80 mg
Updated 5 times since 2017 Last updated: Apr 20, 2011 Started: Nov 30, 2006 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This PHASE2/PHASE3 trial investigates Essential Hypertension and is currently completed. Novartis Pharmaceuticals leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tokyo, Japan